Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of M2951 vs placebo with Tecfidera active control in relapsing multiple sclerosis
2016-001448-21Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of evobrutinib in multiple sclerosis (MS) (3 arms), sponsored by Merck KGaA. Primary endpoint: Number of gadolinium-positive T1 MRI lesions at 24 weeks. Started Oct 2016; status: completed.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2016-001448-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001448-21.